Edwards Lifesciences Corporation revised earnings guidance for the full year 2024. For the year, the company now expects full-year 2024 sales growth to be at the high end of the prior guidance of 8% to 10% and $6.3 billion to $6.6 billion.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
89.16 USD | -1.06% | +2.81% | +16.92% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.92% | 53.72B | |
+12.15% | 227B | |
+14.90% | 197B | |
+18.22% | 141B | |
+29.15% | 110B | |
+0.53% | 64.15B | |
+6.33% | 51.75B | |
+10.93% | 45.2B | |
+5.87% | 37.37B | |
+27.06% | 32.11B |
- Stock Market
- Equities
- EW Stock
- News Edwards Lifesciences Corporation
- Edwards Lifesciences Corporation Revises Earnings Guidance for the Full Year 2024